Ranolazine is a Medicine belongs to Cardiovascular drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 1522   Edition : 37      Page :   Edition :   

  ►   Brandname : Ranexa, Ranozex, Ranozen
  ►  Strength : Tablet (Extended Release Tablets) with 500 mg.  Tablet (Extended Release Tablets) with 1000 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 209   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 1521   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Angina pectoris Oral 375 mg Tablet b.d. For in patients who are unable to tolerate or who have not responded satisfactorily to other antianginals, and should be given as an adjunct to standard therapy. The dose increased after 2 to 4 weeks to 500 mg twice daily. The dose may be further increased after 2 to 4 weeks to 500 mg twice daily. The dose may be further increased to a maximum of 750 mg twice daily depending on response.
2 Angina pectoris Oral 500 mg Tablet b.d. Dose: increasing to a maximum of 1 gtwice daily if necessary. The dose should be limited to 500 mg twice daily in patients taking some interacting drugs.

Ref :-  Book : Martindale    Page : 1521   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
►  Side Effect : Constipation, Dizziness, Nausea, Headache, palpitations, Tinnitus, Vertigo, Dry mouth, Abdominal pain, Vomiting, Peripheral edema, Dyspnoea
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  

►  Drug Interaction : Drug interaction of Ranolazine is with , HIV- protease inhibitors, , , Tricyclic antidepressants, ,  Clarithromycin , Telithromycin, Nefazodone, Diltiazem , Verapamil , Fluconazole , Erythromycin
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Ranolazine is mainly metabolised by the P450 isoenzyme CYP3A4 and may interact with other drugs that affect or are affected by this enzyme. Ranolazine is contra-indicated with potent inhibitors of CYP3A4, such as ketoconazole, and related antifungals, clarithromycin and telithromycin, HIV protease inhibitors, and nafazodone. It may be used with caution in patients taking moderate CYP3A4 inhibitors or P- glycoprotein inhibitors, such as diltiazem, verapamil, fluconazole, erythromycin, ciclosporin, and grapefruit juice or grapefruit products. Ranolazine may itself act as an inhibitor of some enzymes. Plasma concentrations of Simvastatin, which is metabolised by CYP3A4, are reported to be doubled when given with ranolazine. Plasma concentrations of digoxin, P-glycoprotein substrate, may also be increased and dose adjustment may be required; dose reductions may also be needed for drugs metabolised by CYP2D6, such as tricyclic antidepressants and antipsychotics.
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  

►  Contraindication : Pre-existing QT prolongation, Hepatic impairment, Renal impairment
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  
  ►  Mechanism of Action :   Inhibition of cardiac myocyte fatty-acid β-oxidation, inhibition of the delayed rectifier K+ current, and inhibition of the late Na+ current. Inhibition fatty-acid β-oxidation may improve myocardial ATP utilization, while inhibition of Na+ channel activity may reduce the energy required for myocardial repolarization.
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 416   Edition : 3.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Faecal, Renal, Gastrointestinal tract, Hepatic (Metabolism)
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  

►    Plasma Half-life :   Min value :-   7 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 1521   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   2 hours,    Max value :-   5 hours.  
Ref :-   Book : Martindale    Page : 1521   Edition : 37.